Adjuvant IL-15 does not enhance the efficacy of tumor cell lysate-pulsed dendritic cell vaccines for active immunotherapy of T cell lymphoma

Cancer Immunology, Immunotherapy

Volumn 55, Issue 4, 2006, Pages 420-432

  Gatza, Erin ^a   Okada, Craig Y ^b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Dendritic cells; Interleukin 15; Tumor immunity; Vaccination

Indexed keywords

DENDRITIC CELL VACCINE; GAMMA INTERFERON; HERMES ANTIGEN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 15; TUMOR NECROSIS FACTOR ALPHA;

ACTIVE IMMUNIZATION; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL LYSATE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNOSTIMULATION; INNATE IMMUNITY; MEMORY CELL; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE; INTERLEUKIN-15; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL; MICE; MICE, INBRED C57BL; PHENOTYPE; SURVIVAL; TUMOR CELLS, CULTURED;

EID: 30444433811     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0006-9     Document Type: Article

References (46)

1. Barth RJ, Mule' JJ (2000) Interleukin-2: preclinical trials. In: Rosenberg SA (eds) Principles and practice of the biologic therapy of cancer. Lippincott Williams& Wilkins, Philadelphia, pp 19-31
2. Berard M, Brandt K, Bulfone-Paus S, Tough DF (2003) IL-15 promotes the survival of naive and memory phenotype CD8 + T cells. J Immunol 170:5018-5026
3. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, King PD, Larson S, Weiss M, Riviere I, Sadelain M (2003) Eradication of systemic B cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 9:279-286
4. Bulfone-Pau SS, Bulanova E, Pohl T, Budagian V, Durkop H, Ruckert R, Kunzendorf U, Paus R, Krause H (1999) Death deflected: IL-15 inhibits TNF-alpha-mediated apoptosis in fibroblasts by TRAF2 recruitment to the IL-15Ralpha chain. Faseb J 13:1575-1585
5. Dallal RM, Mailliard R, Lotze MT (2000) Cancer vaccines: clinical applications, dendritic cell vaccines. In: Rosenberg SA (eds) Principles and practice of the biologic therapy of cancer. Lippincott Williams& Wilkins, Philadelphia, pp 705
6. Dubois S, Mariner J, Waldmann TA, Tagaya Y (2002) IL-15Rα recycles and presents IL-15 in trans to neighboring cells. Immunity 17:537-547
7. Fehniger TA, Suzuki K, Ponnappan A, VanDeusen JB, Cooper MA, Florea SM, Freud AG, Robinson ML, Durbin J, Caligiuri MA (2001) Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8 + T cells. J Exp Med 193:219-231
8. Fehniger TA, Suzuki K, VanDeusen JB, Cooper MA, Freud AG, Caligiuri MA (2001) Fatal leukemia in interleukin-15 transgenic mice. Blood Cells Mol Dis 27:223-230
9. Fields RC, Shimizu K, Mule JJ (1998) Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 95:9482-9487
10. Gatza E, Okada CY (2002) Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma. J Immunol 169:5227-5235
11. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, Beers C, Richardson J, Schoenborn MA, Ahdieh M et al (1994) Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264:965-968
12. Hart DN, Hill GR (1999) Dendritic cell immunotherapy for cancer: application to low-grade lymphoma and multiple myeloma. Immunol Cell Biol 77:451-459
13. Judge AD, Zhang X, Fujii H, Surh CD, Sprent J (2002) Interleukin 15 controls both proliferation and survival of a subset of memory-phenotype CD8(+) T cells. J Exp Med 196:935-946
14. Kaplan EL, Meiier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:475
15. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, Matsuki N, Charrier K, Sedger L, Willis CR, Brasel K, Morrissey PJ, Stocking K, Schuh JC, Joyce S, Peschon JJ (2000) Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 191:771-780
16. + T cell-mediated immunity in mice infected with a strain of Toxoplasma gondii. J Immunol 163:4503
17. Kiessling R, Klein E, Pross H, Wigzell H (1975) "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol 5:117-121
18. Kiessling R, Klein E, Wigzell H (1975) "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 5:112-117
19. Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, Palmer DC, Tagaya Y, Rosenberg SA, Waldmann TA, Restifo NP (2004) IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 + T Cells. Proc Natl Acad Sci USA 101:1969-1974
20. Kobayashi H, Carrasquillo JA, Paik CH, Waldmann TA, Tagaya Y (2000) Differences of biodistribution, pharmacokinetics, and tumor targeting between interleukins 2 and 15. Cancer Res 60:3577-3583
21. Ku CC, Murakami M, Sakamoto A, Kappler J, Marrack P (2000) Control of homeostasis of CD8 + memory T cells by opposing cytokines. Science 288:675-678
22. Manjunath N, Shankar P, Wan J, Weninger W, Crowley MA, Hieshima K, Springer TA, Fan X, Shen H, Lieberman J, von Andrian UH (2001) Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. J Clin Invest 108:871-878
23. Marks-Konczalik J, Dubois S, Losi JM, Sabzevari H, Yamada N, Feigenbaum L, Waldmann TA, Tagaya Y (2000) IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci USA 97:11445-11450
24. Meazza R, Lollini PL, Nanni P, De Giovanni C, Gaggero A, Comes A, Cilli M, Di Carlo E, Ferrini S, Musiani P (2000) Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: effects on tumorigenicity, metastatic potential and immune response. Int J Cancer 87:574-581
25. Moroz A, Eppolito E, Li Q, Tao J, Clegg CH, Shrikant P (2004) IL-21 enhances and sustains CD8 + T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol 173:900-909
26. Munger W, DeJoy SQ, Jeyaseelan R Sr, Torley LW, Grabstein KH, Eisenmann J, Paxton R, Cox T, Wick MM, Kerwar SS (1995) Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell Immunol 165:289-293
27. O'Neill HC (1991) Radiation leukemia virus-induced T cell lymphomas with common T cell receptor variable region structure and similar binding specificity for retrovirus. Leukemia 5:921
28. Oh S, Berzofsky JA, Burke DS, Waldmann TA, Perera LP (2003) Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc Natl Acad Sci USA 100:3392-3397
29. Okada CY, Wong CP, Denney DW, Levy R (1997) TCR vaccines for active immunotherapy of T cell malignancies. J Immunol 159:5516-5527
30. Peto R, Peto J (1972) Asymptomatically efficient rank invariant test procedures. J R Stat Soc 135:185
31. Piriou L, Chilmonczyk S, Genetet N, Albina E (2000) Design of a flow cytometric assay for the determination of natural killer and cytotoxic T-lymphocyte activity in human and in different animal species. Cytometry 41:289-297
32. Prlic M, Lefrancois L, Jameson SC (2002) Multiple choices: regulation of memory CD8 T cell generation and homeostasis by interleukin (IL)-7 and IL-15. J Exp Med 195:F49-F52
33. Qin J, Zhang C, Kamarashev J, Dummer R, Burg G, Dobbeling U (2001) Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T cell lymphoma cells. Blood 98:2778-2783
34. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian NP, Restifo NP, Dudley ME, Schwarz SL, Spiess P, al e (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321
35. Rubinstein MP, Kadima AN, Salem ML, Nguyen CL, Gillanders WE, Cole DJ (2002) Systemic administration of IL-15 augments the antigen-specific primary CD8 + T cell response following vaccination with peptide-pulsed dendritic cells. J Immunol 169:4928-4935
36. Ruedl C, Rieser C, Bock G, Wick G, Wolf H (1996) Phenotypic and functional characterization of CD11c + dendritic cell population in mouse Peyer's patches. Eur J Immunol 26:1801-1806
37. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708-712
38. Schluns KS, Lefrancois L (2003) Cytokine control of memory T cell development and survival. Nat Rev Immunol 3:269-279
39. Schwartzentruber DJ (2001) Guidelines for the safe administration of high-dose interleukin-2. J Immunother 24:287
40. Waldmann TA, Dubois S, Tagaya Y (2001) Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 14:105-110
41. Weninger W, Crowley MA, Manjunath N, von Andrian UH (2001) Migratory properties of naive, effector, and memory CD8(+) T cells. J Exp Med 194:953-966
42. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R, von Andrian UH, Ahmed R (2003) Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 4:225-234
43. Yajima T, Nishimura H, Ishimitsu R, Watase T, Busch DH, Pamer EG, Kuwano H, Yoshikai Y (2002) Overexpression of IL-15 in vivo increases antigen-driven memory CD8 + T cells following a microbe exposure. J Immunol 168:1198-1203
44. Yajima T, Nishimura H, Wajjwalku W, Harada M, Kuwano H, Yoshikai Y (2002) Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T cell response. Int J Cancer 99:573-578
45. Yamada N, Sugawara I, Hata T, Tsuruta K, Moriuchi R, Maeda T, Atogami S, Murata K, Fujimoto K, Kohno T, Tsukasaki K, Tomonaga M, Hirakata Y, Kaminihira S (1998) Interleukin-15 (IL-15) can replace the IL-2 signal in IL-2-dependent adult T cell leukemia (ATL) cell lines: expression of IL-15 receptor α on ATL cells. Blood 91:4265-4272
46. Zhang X, Sun S, Hwang I, Tough DF, Sprent J (1998) Potent and selective stimulation of memory-phenotype CD8 + T cells in vivo by IL-15. Immunity 8:591-599